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There is growing evidence that oxysterols are more than simple metabolites in the pathway from cholesterol to
bile acids. Recent data has shown oxysterols to be ligands to nuclear receptors and to G protein-coupled re-
ceptors, modulators of N-methyl-D-aspartate receptors and regulators of cholesterol biosynthesis. In this mini-
review we will discuss the biosynthetic mechanisms for the formation of diﬀerent oxysterols and the implication
of disruption of these mechanisms in health and disease.
1. Introduction
Oxysterols are oxidised forms of cholesterol or of its precursors
[1,2]. They are early intermediates in the metabolism of cholesterol to
bile acids. Oxysterols possess a wide range of biological properties
acting as ligands towards nuclear receptors [3–6] and to G protein-
coupled receptors (GPCRs) [7–12] and modulators of N-methyl-D-as-
partate receptors (NMDARs) [13]. Oxysterols also bind to INSIG (in-
sulin induced gene) tethering SCAP (SREBP cleavage-activating pro-
tein) and SREBP-2 (sterol regulatory-element binding protein-2) in the
endoplasmic reticulum (ER), preventing transport of SREBP-2 to the
Golgi for processing to its active form as a transcription factor for the
genes of the cholesterol biosynthesis pathway [14].
In vertebrates, oxysterols are mostly synthesised in enzyme cata-
lysed reaction [15] but can also be formed via non-enzymatic routes
[16–18]. The main enzymes responsible for introducing hydroxy groups
to generate oxysterols are members of the cytochrome P450 (CYP) su-
perfamily, while further oxidation may proceed by additional action of
CYPs or hydroxysteroid dehydrogenase (HSD) enzymes. Cholesterol 25-
hydroxylase (CH25H) is an exception in that it is a not a CYP but
member of a family of enzymes that use diiron co-factors to catalyse
hydroxylation [19].
2. Main pathways of oxysterol biosynthesis
Oxysterol biosynthesis can be divided into a number of diﬀerent
pathways depending on the site of the initial oxidation, these pathways
may overlap and lead ultimately to bile acid formation.
2.1. 7α-Hydroxylase pathway
This embraces the “neutral” or “classical” pathway of bile acid
biosynthesis and intermediates include 7α,(25R)26-dihydrox-
ycholesterol (7α,26-diHC, unless speciﬁcally stated stereochemistry is
assumed to be 25R, also known as 7α,27-dihydroxycholesterol) a ligand
to the GPCR183 (Epstein-Barr virus induced gene 2, EBI2) [7,8].
The ﬁrst step of the pathway is 7α-hydroxylation of cholesterol by
CYP7A1, the transcript of which is almost exclusively expressed in liver
(Supplemental Table S1) [20–22], to give 7α-hydroxycholesterol
(7α−HC). This is the rate determining step in the “neutral” pathway of
bile acid biosynthesis. 7α−HC may be (25R)26-hydroxylated then
(25R)26-carboxylated by CYP27A1, expressed in multiple organs
[21–23], to 7α,26-diHC and 3β,7α-dihydroxycholest-5-en-(25R)26-oic
acid (3β,7α-diHCA), respectively (Fig. 1). Alternatively, 7α−HC may
be oxidised by ubiquitously expressed HSD3B7 [21,22,24] to 7α-hy-
droxycholest-4-en-3-one (7α−HCO). 7α−HCO is a ligand to the
pregnane X receptor (PXR), a member of the nuclear receptor super-
family [25]. Another route for 7α−HC metabolism is by CYP3A4 in
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Fig. 1. 7α-Hydroxylase and (25R)26-hydroxylase pathways of oxysterol biosynthesis. The 7α-hydroxylase pathway starts with 7α-hydroxylation of cholesterol and
the (25R)26-hydroxylase pathway begins with (25R)26-hydroxylation of cholesterol.
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human, and CYP3A11 in mouse, to the most potent EBI2 agonist 7α,25-
dihydroxycholesterol (7α,25-diHC) and also to a lesser extent 7α,(25S)
26-dihydroxycholesterol (7α(25S)26-diHC) [26]. PXR is activated by
7α−HCO [25] and regulates the expression of CYP3A4 in human, 3A11
in mouse [27]. HSD3B7 requires a 7α-hydroxy group in its substrates
and can oxidise 7α,26-diHC, 7α,25-diHC and 3β,7α-diHC to their re-
spective 3-oxo-4-ene equivalents 7α,(25R)26-dihydroxycholest-4-en-3-
one (7α,26-diHCO), 7α,25-dihydroxycholest-4-en-3-one (7α,25-
diHCO) and 7α-hydroxy-3-oxocholest-4-en-(25R)26-oic acid (7αH,3O-
CA). The ultimate metabolite of the “neutral” pathway is predominantly
cholic and to a lesser extent chenodeoxycholic acid. In cholic acid
biosynthesis CYP8B1 introduces a 12α-hydroxy group into 7α−HC and
7α−HCO to give 7α,12α-dihydroxycholesterol (7α,12α-diHC) and
mostly 7α,12α-dihydroxycholest-4-en-3-one (7α,12α-diHCO) [28,29].
In the “classical” bile acid biosynthesis pathway 7α,12α-diHCO
becomes reduced by aldoketo reductase 1D1 (AKR1D1) then AKR1C4 to
5β-cholestane-3α,7α,12α-triol which is a substrate for CYP27A1 oxi-
dation ﬁrst to the 3α,7α,12α,(25R)26-tetrol and then the 3α,7α,12α-
trihydroy-5β-cholestan-(25R)26-oic acid which is then side-chain
shortened to cholic acid in the peroxisome [30–32]. Alternatively,
7α,12α-diHC, 7α,12α-diHCO, 7α,26-diHC, 7α,26-diHCO can cross into
the (25R)26-hydroxylase pathway and 7α,25-diHC and 7α,25-diHCO
fall into the “25-hydroxylase” pathways as described below (Fig. 1).
The expression of CYP7A1, the gene encoding the rate-limiting step
of the “neutral” pathway of bile acid biosynthesis, and of CYP8B1, is
regulated by the farnesoid X receptor (FXR), activated by cholic and
chenodeoxycholic acids [33,34]. FXR activates another nuclear re-
ceptor, short hetrodimeric partner (SHP), which binds and inhibits a
third nuclear receptor, liver receptor homologue 1 (LRH-1), which ac-
tivates the expression of CYP7A1 and CYP8B1 [15]. The net result of
activation of FXR by bile acids is inhibition of CYP7A1 expression and
their own biosynthesis. In mouse CYP7A1 expression is also regulated
by the liver X receptor (LXR) [35].
2.2. 25-Hydroxylase pathway
The “25-hydroxylase” pathway is considered to start with 25-hy-
droxylation of cholesterol by CH25H (Fig. 2) [19]. CH25H is located on
chromosome 10 in man, while Ch25h is located on chromosome 19 in
mouse. It is an interferon-stimulated gene expressed in activated im-
mune cells [36–38]. The enzyme product 25-hydroxycholesterol
(25−HC) supresses cholesterol synthesis and is a ligand to the LXRs and
to INSIG [3,14], suppresses interlukin-1 driven inﬂammation [39,40]
and inhibits viral infection in a paracrine manner [38,41]. There is only
one report of CH25H deﬁciency in human, but the disorder presented
with combined deﬁciency of the adjacent gene lysosomal acid lipase
(LIPA), and the ﬁrst patient was initially diagnosed with Wolman dis-
ease (infantile onset lysosomal acid lipase deﬁciency) [42]. Patients
presented with susceptibility to abyss in response to Bacillus Calmet-
te–Guérin (BCG) vaccination [42]. CYP3A4 can also act as an alter-
native cholesterol 25-hydroxylase, accounting for production of
25−HC in the absence of CH25H [43].
25−HC is metabolised by CYP7B1 to the EBI2 ligand 7α,25-diHC
[7,44]. Deﬁciency in CYP7B1 leads to oxysterol 7α-hydroxylase deﬁ-
ciency in infants [45] and hereditary spastic paraplegia type 5 (SPG5)
in adults [46], although the SPG5 phenotype is believed to be a con-
sequence of disruption of the (25R)26-hydroxylase pathway rather than
the 25-hydroxylase pathway. CYP7B1 is expressed in many tissues [21].
By virtue of the presence of a 7α-hydroxy group, 7α,25-diHC is a
substrate for HSD3B7 and can be converted to 7α,25-diHCO. The exact
routes for metabolism of 7α,25-diHCO are still to be fully established.
One pathway is further oxidation, initially by CYP8B1 at C-12, then at
C-24 ﬁrst to an alcohol, by CYP3A4 in man and CYP3A11 in mouse
[27], then to a carbonyl followed by elimination of acetone with sub-
sequent bile acid formation as suggested by Duane et al [47]. Reduction
and oxidation, presumably by AKR1D1 and AKR1C4 may precede
before [32] or after 24-hydroxylation [48]. We have recently uncovered
an unexpected 25-hydroxylated acid, 7α,25-dihydroxy-3-oxocholest-4-
en-26-oic acid (7α,25-diH,3O-CA) in human plasma and cerebrospinal
ﬂuid (CSF) [49]. Interestingly, its level is reduced in CSF from patients
suﬀering from Alzheimer’s disease [48]. Correlation analysis of cho-
lesterol metabolites found in CSF suggests that 7α,25-diHCO, 7α,25-
diH,3O-CA and 7α-hydroxy-3-oxochol-4-en-24-oic acid (7αH,3O-Δ5-
BA) constitute a pathway towards chenodeoxycholic acid [48].
2.3. 24S-Hydroxylase pathway
Cholesterol is metabolised to 24S-hydroxycholesterol (24S−HC) by
CYP46A1 (Fig. 2). 24S−HC is a ligand to both LXRs and INSIG [3,14].
Unlike cholesterol, 24S−HC can cross the blood brain barrier (BBB)
and represents a route to removal of cholesterol from brain [50], be-
sides regulating cholesterol synthesis through INSIG and the SREBP-2
pathway. In human and mouse CYP46A1 is expressed in brain [51].
There is some minor expression of the gene in other tissues including
testis and ovary [21,22], however, at least in mouse, 24S−HC found in
the circulation is derived predominantly from brain [52]. 24S−HC is
7α-hydroxylated to 7α,24S-diHC by CYP39A1 [53]. The gene is ex-
pressed mostly in liver but also in brain [21,22]. 7α,24S-diHC can be
oxidised by HSD3B7 to 7α,24S-dihydroxycholest-4-en-3-one (7α,24S-
diHCO) which is found in mouse brain and plasma [26,54]. 7α,24S-
diHC has been found in human plasma [55]. 7α,24S-diHC and 7α,24S-
diHCO may provide substrates for CYP27A1 and crossover to the (25R)
26-hydroxylase pathway (see below). 7α,24-Dihydroxy-3-oxocholest-4-
en-26-oic acid (7α,24-diH,3O-CA) has been identiﬁed in human plasma
and CSF [48,49]. As discussed below 7α,24S-diH,3O-CA undergoes
side-chain shortening in the peroxisome to 7αH,3O-Δ5-BA which can
then be reduced by AKR1D1 and AKR1C4 to chenodeoxycholic acid.
2.4. (25R)26-hydroxylase pathway
The (25R)26-hydroxylase pathway begins with (25R)26-hydro-
xylation of cholesterol by CYP27A1 to give (25R)26-hydroxycholesterol
(26−HC, 25R-stereochemistry is assumed unless indicated otherwise,
also called 27-hydroxycholesterol) which can be further oxidised to 3β-
hydroxycholest-5-en-(25R)26-oic acid (3β−HCA) by the same enzyme
(Fig. 1). A defect in the enzyme CYP27A1 leads to the disorder cere-
brotendinous xanthomatosis (CTX) [56], where this pathway is in-
active. In contrast to human, deﬁciency in CYP27A1 enzyme activity in
mouse, as revealed by the Cyp27a1 knock-out (Cyp27a1-/-) animal,
leads to only a mild phenotype [57]. There are two branches of the
(25R)26-hydroxylase pathway, the ﬁrst starts from 26−HC with 7α-
hydroxylation give 7α,26-diHC and the second from 3β−HCA with 7α-
hydroxylation to give 3β,7α-diHCA, both reactions being catalysed by
CYP7B1. The pathway from 3β−HCA is the “acidic” or “alternative”
pathway of bile acid biosynthesis [15]. 26−HC, 3β−HCA and 3β,7α-
diHCA can act as LXR ligands [58–61], while 26−HC will also repress
cholesterol synthesis by binding to INSIG [14]. 26−HC has been shown
to be a selective estrogen receptor modulator (SERM) and has been
implicated with breast cancer [62,63]. The EBI2 ligand 7α,26-diHC can
be deactivated by HSD3B7 to 7α,26-diHCO, or by CYP27A1 to 3β,7α-
diHCA. 7α,26-diHCO can be oxidised further by CYP27A1 to 7αH,3O-
CA. The two branches of the 26-hydroxylase pathway converge at
7αH,3O-CA with HSD3B7 oxidation of 3β,7α-diHCA. Interestingly,
3β−HCA and 3β,7α-diHCA are both ligands to LXR but have opposite
eﬀects on oculomotor neuron survival during development [59]. Re-
duction in the A-ring of 7αH,3O-CA by AKR1D1 and AKR1C4 can
proceed before or after side-chain shortening in the peroxisome to ul-
timately lead to chenodeoxycholic acid [32].
3. Peroxisomal side-chain shortening
Peroxisomes are organelles important for the β-oxidation and side-
W.J. Griﬃths and Y. Wang Prostaglandins and Other Lipid Mediators 147 (2020) 106381
3
chain shortening of bile acids. They also serve to conjugate newly
synthesised bile acids with glycine or taurine. Patients suﬀering from
Zellweger syndrome, which results from an absence of functional
peroxisomes, show an accumulation of C27 bile acids [64]. Zellweger
syndrome is an autosomal recessive disorder and presents with im-
paired brain development, degeneration of central nervous system
Fig. 2. 24S-Hydroxylase and 25-hydroxylase pathways of oxysterol biosynthesis.
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myelin and enlarged liver. Children with this disorder usually die
within the ﬁrst year reﬂecting the essential functions of the peroxisome
[65].
Cholestenoic and cholestanoic acids can be included in the oxysterol
family hence their side-chain shortening reactions are discussed here. In
the following section we will describe side-chain shortening for
7αH,3O-CA but the same reaction sequence is applicable to A-ring
reduced and also to 12α-hydroxy metabolites.
The ﬁrst step is to form a CoA-thioester, this is achieved by bile acid
CoA ligase (or synthetase, BACS, SLC27A5) or by very-long chain acyl-
CoA synthetase (VLCS, SLC27A2, Fig. 3). BACS is a microsomal protein
mostly expressed in liver, while VLCS is expressed mostly in liver and
kidney and is present in the ER and peroxisome [21,22]. The ABC
transporter protein ABCD3 is required to transport C27-bile acyl-CoAs
Fig. 3. Peroxisomal side-chain shortening.
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into the peroxisome. When the acyl-CoA is derived from the “acidic”
pathway it will have 25R stereochemistry. However, for peroxisomal
side-chain shortening it is ﬁrst necessary to convert this to the 25S-
epimer. This is achieved by the broadly expressed α-methylacyl-CoA
racemase (AMACR) [21,22], mutations in which can lead to AMACR
deﬁciency [66,67]. Next, a double bond with E stereochemistry is in-
troduced between C-24 and C-25 by acyl-CoA oxidase 2 (ACOX2). Pa-
tients with ACOX2 deﬁciency were discovered in 2016 by Vilarinho
et al showing liver ﬁbrosis, ataxia and cognitive impairment [68]. The E
double bond is next hydrolysed by the hydratase activity of D-bifunc-
tional protein (DBP, MFE2, HSD17B4) to give the 24R-hydroxy-(25R)
26-acyl-CoA, which is then oxidised to the 24-oxo-(25R)26-acyl-CoA by
the HSD activity of DBP. Sterol carrier protein x (SCPx, SCP2) catalyses
the last step in β-oxidation to give the C24-acyl-CoA which can be
conjugated with glycine or taurine by bile acyl-CoA : amino acid N-acyl
transferase (BAAT) or hydrolysed to the C24 carboxylic acid by perox-
isomal acyl-CoA thioesterase (ACOT) [69,70]. Patients with deﬁ-
ciencies in DBP [71], SCPx [72] and BAAT [73] have been discovered.
When initial hydroxylation of cholesterol is by CYP46A1 to give
24S−HC, the down-stream C27 acid prior to peroxisomal processing has
24S-hydroxy-(25R)26-carboxylate stereochemistry. This stereo-
chemistry in the subsequent acyl-CoA thioester provides a substrate for
HSD activity of L-bifunctional protein (LBP, MFP1, enoyl-CoA hy-
dratase and 3-hydroxyacyl CoA dehydrogenase, EHHADH) to generate
24-oxo-(25R)26-acyl-CoA for further processing by SCPx. In mouse
24R−HC is present in plasma [52], metabolism to the down-stream
24R-hydroxy-(25R)26-acyl-CoA will provide a substrate for the HSD
activity of DBP to generate the 24-oxo-(25R)26-acyl-CoA which can
then undergo side-chain shortening.
Bile acids can be formed in the absence of CYP27A1. This is evident
in patients with CTX and in the Cyp27a1-/- mouse [26,56]. In the
Cyp27a1-/- mouse there is some sterol (25S)26-hydroxylase activity.
This has been suggested to be via CYP11A1 in mouse and CYP3A4 in
man [26,27]. We have suggested a pathway to C27-(25S)26-acyl-CoA’s
which are substrates for ACOX2 [26].
4. Other pathways of oxysterol biosynthesis and metabolism
4.1. 7-Oxocholesterol and 7β-hydroxycholesterol pathways
4.1.1. Smith-Lemli-Opitz syndrome
7-Oxocholesterol (7−OC) can be formed from 7-dehydrocholesterol
(7-DHC) by CYP7A1 [74] (Fig. 4). It can then be reduced to 7β-hy-
droxycholesterol (7β−HC) by HSD11B1, the same enzyme that reduces
cortisone to cortisol [75–77]. HSD11B2 catalyses the reverse reaction
[12]. We have shown that in the disorder, Smith-Lemli-Opitz syndrome
(SLOS) where 7-DHC is abundant, on account of a defect in 7-deh-
drocholesterol reductase (DHCR7), 26-hydroxy-7-oxocholesterol
(26H,7O-C) and 25-hydroxy-7-oxocholesterol (25H,7O-C) are evident
in plasma, as are their 7β-reduced forms, presumably formed by
HSD11B1 from the 7-oxo precursors [78–81]. 26H,7O-C, 25H,7O-C and
7β,26-dihydroxycholesterol (7β,26-diHC, also called 7β,27-dihydrox-
ycholesterol) will bind to the extracellular cysteine rich domain (CRD)
of Smoothened (SMO), the GPCR involved in the Hedgehog (Hh) sig-
nalling pathway and activate the pathway [10,12]. Disturbed Hh sig-
nalling is implicated in the SLOS phenotype, which is a disorder pre-
senting with dysmorphology [82]. Data from analysis of plasma from
people with SLOS and from amniotic ﬂuid of aﬀected pregnancies
shows that 26H,7O-C and 7β,26-diHC both cross into the “acidic”
pathway of bile acid biosynthesis with formation of 3β-hydroxy-7-ox-
ocholest-5-en-26-oic (3βH,7O-CA) and 3β,7β-diHCA (Fig. 4). 3βH,7O-
CA can also modulate Hh signalling by binding to the CRD of SMO
[78,79], while 3β,7β-diHCA is a ligand to the nuclear receptor RAR-
related orphan receptor gamma t (RORγt) [5]. In the absence of a 7α-
hydroxy group, 7β-hydroxy and 7-oxosterols cannot undergo transfor-
mation of the 3β-hydroxy-5-ene structure to the 3-oxo-4-ene by
HSD3B7, hence the 3β-hydroxy-7-oxo-5-ene and 3β,7β-dihydroxy-5-
ene structures are maintained through bile acid biosynthesis to the 3β-
hydroxy-7-oxochol-5-en-24-oic (3βH,7O-Δ5-BA) and 3β,7β-dihydrox-
ychol-5-en-24-oic (3β,7β-diH-Δ5-BA) acids and their glycine and
taurine conjugates [55,78,79]. The 7β-hydroxy group can be con-
jugated with N-acetylglucosamine (GlcNAc) in a reaction catalysed by
UGT3A1 [83] and bile acids conjugated with GlcNAc and glycine or
taurine and sulphuric acid have been identiﬁed in SLOS patients [79].
4.1.2. Lysosomal storage disorders; Niemann pick disease types B and C
and Wolman’s disease
The lysosomal storage disorder Niemann Pick (NP) disease type B
results from mutations in the sphingomyelin phosphodiesterase 1
(SMPD1) gene, while NP disease types C1 and C2 result from mutations
in the NPC1 and NPC2 genes, respectively. Mutations in all three pro-
teins lead to a similar clinical phenotype with accumulation of non-
esteriﬁed cholesterol in late endosomes/lysosomes [84]. The NPC1 and
NPC2 proteins are involved in export of non-esteriﬁed cholesterol from
the lumen of late endosomes/lysosomes. Within late endosomes/lyso-
somes the soluble NPC2 protein shuttles cholesterol to the membrane
bound NPC1 protein, avoiding contact of the sterol with the aqueous
environment. The mechanism by which NPC1 transports cholesterol
from the late endosomes/lysosomes to the ER and plasma membrane
has yet to be established [84]. A further protein in lysosomes is lyso-
somal acid lipase (LAL), coded by the LIPA gene on chromosome 10 in
human, which hydrolyses cholesterol esters taken up in LDL by receptor
mediated endocytosis into endosomes, making non-esteriﬁed choles-
terol available for NPC transport [85]. In infants LAL deﬁciency pre-
sents as Wolman’s disease, primarily characterised by accumulation of
cholesterol esters and triglycerides in liver spleen and lymph nodes
[85]. Diagnostic features of both NPB and NPC are elevated plasma
levels of 7−OC and cholestane-3β,5α,6β-triol (3β,5α,6β-triol) [86].
3β,5α,6β-Triol is generated by hydrolysis of 5,6-epoxycholesterol (5,6-
EC) by the enzyme cholesterol epoxide hydrolase (ChEH) [87]. ChEH is
heterodimer of two other enzymes, 3β-hydroxysterol-Δ8-Δ7-isomerase
(D8D7I, EBP, emopamil-binding protein) and DHCR7. An enzyme
converting cholesterol to 5,6-EC has yet to be established and it is likely
that it is formed in lysosomal storage disorders by non-enzymatic oxi-
dation in late endosomes/lysosomes (Fig. 4). An alternative metabolic
route for metabolism of 5α,6-EC, but not 5β,6-EC, is conjugation with
histamine to give dendrogenine A (DDA), in a reaction catalysed by
DDA synthase (Fig. 5). DDA shows tumour suppressor properties
[88,89]. Interestingly, DDA is a partial agonist of LXR triggering au-
tolysosome formation [88].
There appear to be two routes for metabolism of 3β,5α,6β-triol, one
route is metabolism to 3β,5α,6β-trihydroxycholan-24-oic acid
(3β,5α,6β-triHBA) and its conjugates [55,83,90,91], the other, oxida-
tion by HSD11B2 to the oncometabolite 3β,5α-dihydroxycholestan-6-
one (3β,5α-diHC-6O, 6-oxo-cholestan-3β,5α-diol, OCDO, Fig. 5) [6].
3β,5α-diHC-6O stimulates cell growth by binding to the glucocorticoid
receptor [6]. By analysis of plasma from patients with NPB, NPC and
Wolman’s disease, LIPA deﬁciency presenting in infants, where
3β,5α,6β-triol is abundant, a metabolic pathway where 3β,5α,6β-triol
is oxidised by CYP27A1 and proceeds along the same route as the
“acidic” pathway has been established [55].
As in SLOS, elevated plasma levels of 7−OC and 7β−HC are found
patients with NPB, NPC and Wolman’s disease and become metabolised
in pathways identical to those described for SLOS [55,91]. 7-DHC is not
elevated in these lysosomal storage disorders and it is highly likely that
7−OC and 7β−HC are derived via non-enzymatic oxidation of cho-
lesterol [55]. It is of interest, that as far back as 2001 Alvelius et al
described unusual 7-oxo-bile acids in a patient with NPC [92], while as
early as 1994 Natowski and Evans described abnormal bile acids in
urine from SLOS patients [93]. On account of its formation through
non-enzymatic oxidation the metabolism of 7−OC has been of interest
for decades [94,95].
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Fig. 4. Cholesterol epoxide hydrolase, 7β-hydroxy and 7-oxo pathways of oxysterol biosynthesis.
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4.2. 24S,25-Epoxycholesterol synthesis and metabolism
24S,25-Expoxycholesterol (24S,25-EC) can be formed via a shunt of
the mevalonate pathway, using the same enzymes as in cholesterol
biosynthesis with the exception of 24-dehydrocholesterol reductase
(DHCR24), which is not utilised in the shunt pathway (Fig. 6) [96,97].
In the shunt pathway, squalene epoxidase (SQLE) introduces a second
epoxy group into squalene to give squalene-2,3(S);22(S),23-dioxide,
rather than the normal squalene-2,3(S)-oxide. Squalene-
2,3(S);22(S),23-dioxide is then cyclised by lanosterol synthase (LSS)
and metabolised in parallel to lanosterol in the Block pathway to give
24S,25-EC. An alternative route to biosynthesis of 24S,25-EC is by
epoxidation of the C24 - C25 double bond in desmosterol by CYP46A1
[98]. 24S,24-EC has been found to be elevated in brain and plasma of
mice over expressing the human CYP46A1 enzyme [99]. This is com-
patible with formation of 24S,24-EC from desmosterol via CYP46A1
catalysis in brain, but could also be explained by an increased passage
of metabolites through the mevalonate pathway, and its shunt, as a
consequence of enhanced cholesterol removal by CYP46A1 metabolism
and a reduction in negative-feedback of the pathway by cholesterol
[100].
24S,25-EC is underreported in oxysterol analysis because of diﬃ-
culties in its detection by mass spectrometry. It is a bioactive molecule,
acting as a ligand to the LXRs [3], to INSIG [14] and has recently been
shown to bind to SMO and activate the Hh pathway [12,101]. Theoﬁ-
lopoulos et al have shown that 24S,25-EC promotes midbrain motor
neuron neurogenesis through activation of the LXR receptors [99,102].
The likely metabolic route of 24S,25-EC is 7α-hydroxylation to 3β,7α-
dihydroxycholest-5-en-24S,25-epoxide by CYP7B1 [54,103].
4.3. 22R-Hydroxylase pathway
The ﬁrst step of steroid hormone biosynthesis is the 22R-hydro-
xylation of cholesterol by CYP11A1 (P450scc) to give 22R-hydro-
xycholesterol (22R−HC). This is followed by a second hydroxylation by
the same enzyme to give 20R,22R-dihydroxycholesterol (20R,22R-
diHC) which undergoes side-chain cleavage to pregnenolone catalysed
by the same enzyme (Fig. 7). Both 22R−HC and 20R,22R-diHC are
found in mouse plasma [26]. Recent unpublished data from our la-
boratory shows that 20R,22R-diHC is particularly abundant in plasma
from human mothers’ umbilical cord blood. This is perhaps not sur-
prising as CYP11A1 is highly expressed in placenta [21].
4.4. 20S-Hydroxycholesterol pathway
20S-Hydroxycholesterol (20S−HC) is the most potent oxysterol
Fig. 5. Metabolism of 5α,6-epoxycholesterol.
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agonist towards the Hh signalling pathway. It binds to the CRD of SMO
[9]. 20S−HC is an elusive oxysterol with few deﬁnitive identiﬁcations
[104]. However, Lin et al identiﬁed 20S−HC in rat brain and in human
placenta [105]. We have similarly found 20S−HC to be in mouse brain
and also human placenta [106]. It is not clear which enzyme generates
20S−HC, the KEGG pathway https://www.genome.jp/kegg-bin/
show_pathway?map00140+C05501 implicates CYP11A1 but the lit-
erature does not appear to be in accord with this.
4.5. Oxysterols derived from cholesterol precursors
As discussed for 24S,25-EC above, oxysterols can be generated from
cholesterol precursors as well as cholesterol itself.
4.5.1. Desmosterol
Björkhem and colleagues have created a mouse model of the human
disorder desmosterolosis, where DHCR24 is dysfunctional [107,108].
Surprisingly, the mice had only a mild phenotype [107]. Analysis of
plasma from the Dhcr24-/- mouse revealed the presence of 26-hydro-
xydesmosterol (26-HD, also called 27-hydroxydesmosterol) but not 7α-
hydroxydesmosterol (7α-HD), although desmosterol is a substrate for
both CYP27A1 and CYP7A1 (Fig. 6) [108]. More recent studies have
identiﬁed both the (Z) and (E) isomers of 26-HD in mouse brain [54]
and 7α-HD in the circulation of the Cyp27a1-/-mouse where CYP7A1 is
up-regulated [26]. While desmosterol acts as an LXR ligand [108,109],
neither of the 26-HD isomers are active, providing a route to deacti-
vation of desmosterol [110].
4.5.2. 7-DHC and 8-DHC
Besides the pathway discussed above where CYP7A1 converts 7-
DHC to 7−OC, there are other pathways from 7-DHC, both enzymatic,
and non-enzymatic, to oxysterols (Fig. 8) [74,98,111]. 7-DHC is ele-
vated in the disorder SLOS where DHCR7 is deﬁcient. 7-DHC will iso-
merise to 8-DHC and metabolites of both these sterols are evident in
plasma from SLOS subjects. In recent studies we have identiﬁed en-
zymatically derived 7,8-epoxycholesterol (7,8-EC, 3β-hydroxycholest-
5-en-7,8-epoxide), 24- or 25-hydroxy-8-dehydrocholesterol (24H-8-
DHC or 25H-8-DHC) and 26-hydroxy-8-dehydrocholesterol (26H-8-
DHC) in plasma from SLOS patients (Fig. 8) [112,113]. Others have
identiﬁed 26-hydroxy-7-dehydrocholesterol (26H-7-DHC), 26H-8-DHC
and 4α- and 4β-hydroxy-7-dehydrocholesterol (4αH-7-DHC, 4βH-7-
DHC) in SLOS plasma [114,115]. Both 26H-7-DHC and 25-hydroxy-7-
dehydrocholesterol (25H-7-DHC) were found to be partial activators of
LXRs [114,115].
7-DHC is susceptible to free radical oxidation reactions which may
proceed in vivo and ex vivo [111,116]. A prominent 7-DHC metabolite
formed in ﬁbroblasts from SLOS patients is 3β,5α-dihydroxycholest-7-
en-6-one. This oxysterol is present in plasma from SLOS patients [113].
It blocks Hh signalling by binding to SMO at a binding site distinct from
other oxysterols [11].
5. Discussion
Oxysterols are formed through a myriad of enzyme catalysed and
non-enzymatic reactions. They have a very wide range of properties
Fig. 6. Biosynthesis of 24S,25-epoxycholesterol and of other oxysterols from desmosterol.
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including acting as ligands to nuclear receptors including the LXRs
[3,58–61,88], PXR [25], RORγt [5], the estrogen receptors [4] and the
glucocorticoid receptor [6]. They bind to INSIG and inhibit the pro-
cessing of SREBP-2 to its active form as a transcription factor [14] and
they also bind to and modulate the NMDARs [13]. More recently,
oxysterols have been shown to be ligands to GPCRs.
In 2011, 7α,25-diHC and 7α,26-diHC were discovered to be ligands
to GPCR183 known EBI2 [7,8]. Both 7α,25-diHC and 7α,26-diHC act as
chemo-attractants to cells expressing EBI2, directing cell migration.
Mice deﬁcient in EBI2 or in CH25H fail to position activated B cells
within the spleen to the outer follicle and mount a reduced plasma cell
response after an immune challenge, indicating a role for 7α,25-diHC in
the immune response [7]. Numerous follow-up studies have implicated
oxysterols and EBI2 in inﬂammatory disorders, including neuroin-
ﬂammation [117,118]. However, 25−HC, one of the precursor oxy-
sterol to 7α,25-diHC, appears to have pro- and anti-inﬂammatory
properties in diﬀerent situations. Cyster, Russell and co-workers have
deﬁned an anti-inﬂammatory activity of 25−HC through prevention of
AIM2 inﬂammasome activation in macrophages [39,40]. They showed
that this is through inhibition of the SREBP-2 pathway and reduced
synthesis of cholesterol [40]. Their results are consistent with data from
Crick et al who showed that levels of 25−HC are reduced in plasma
from patients with the inﬂammatory disorder multiple sclerosis [119].
On-the-other hand Vigne et al showed 25−HC acting through LXR to
dampen the response of regulatory T cells, resulting in a pro-in-
ﬂammatory response [120]. Clearly more work is required to under-
stand how 25−HC, 7α,25-diHC and their synthetic enzymes act under
diﬀerent conditions in diﬀerent types of immune cell.
SMO is a Class F GPCR [121]. It is a key component of the Hh
signalling pathway required for proper cell diﬀerentiation and
malfunction of the pathway leads to basal cell carcinoma [122]. SLOS
phenocopies a defective Hh signalling pathway presenting with dys-
morphology [82]. Oxysterols have been known for many years to be
modulators of the Hh pathway through binding to SMO [9,123]. As
discussed above, these include a wide range of structures ranging from
the side-chain oxysterols 24S,25-EC and 20S−HC to B-ring oxysterols
7β,26-diHC and 26H,7−OC through to 3β,5α-dihydroxycholest-7-en-6-
one [9–12]. Interestingly, 3β,5α-dihydroxycholest-7-en-6-one appears
to act in a diﬀerent way to the side-chain and other B-ring oxysterols in
that it binds to a diﬀerent site on SMO and inhibits rather than activates
the Hh pathway [11]. 3β,5α-Dihydroxycholest-7-en-6-one and the
other B-ring oxysterols have been identiﬁed in plasma from SLOS pa-
tients, further linking dysfunctional Hh signalling to this disorder
[113].
In summary, oxysterols were once regarded as uninteresting inter-
mediates in bile acid and steroid hormone biosynthesis. That view has
changed with compelling evidence for their biological activities in-
cluding acting as lipid mediators in physiologic and pathologic condi-
tions. The observed modiﬁcations of oxysterol metabolite proﬁles in
numerous diseases (age related diseases, neurological diseases, etc)
could be of value in identifying new pharmacological targets and in
development of eﬃcient treatments.
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